Core Insights - Resmed Inc. (RMD) is experiencing strong demand for its AirSense 10 and AirSense 11 sleep devices, with promising international market expansion supported by stable solvency [1][9] - The stock has increased by 5.1% over the past year, outperforming the industry which declined by 3.2%, while the S&P 500 rose by 19.5% during the same period [1] Company Performance - Resmed has a market capitalization of $36.23 billion and an earnings yield of 4.4%, which is favorable compared to the industry's flat yield [2] - The company has consistently surpassed earnings estimates in the last four quarters, with an average surprise of 3.04% [2] Growth Opportunities - The company is focusing on expanding into high-growth international markets such as China, South Korea, India, Brazil, and Eastern Europe, aiming to enhance patient quality of life and reduce healthcare costs [3] - In Q1 FY26, combined sales in the U.S., Canada, Latin America, Europe, and Asia increased by 10% [4] - Global device sales rose by 9% in Q1 FY26, with an 8% increase in the U.S., Canada, and Latin America, and an 11% increase in Europe, Asia, and other markets [5][9] - The AirSense 11 platform is being launched in more countries, including India, and a new version for sleep lab environments has been introduced [6] Financial Health - As of September 30, 2025, Resmed had a long-term debt of $408.7 million, significantly lower than its cash and cash equivalents of $1.38 billion, with a total debt-to-capital ratio of 6.3% [7][9] Challenges - Resmed's operations are affected by macroeconomic conditions, geopolitical instability, and supply chain constraints, which may lead to increased costs and impact profitability [10] - SG&A expenses rose by 9.5% year-over-year in the fiscal first quarter [10] Earnings Estimates - The Zacks Consensus Estimate for RMD's fiscal 2026 earnings per share (EPS) has increased by 0.2% to $10.84, with revenue estimates at $5.58 billion, reflecting an 8.4% increase from the previous year [11]

Core Insights - Boston Scientific (BSX) and Resmed (RMD) are significant players in the global medical devices market, with market capitalizations of $142.4 billion and $35.72 billion, respectively [2] - The medical devices market is projected to grow at nearly 7% CAGR from 2025 to 2030, prompting an evaluation of investment opportunities in both companies [3] Boston Scientific Overview - Boston Scientific is experiencing strong performance in its Cardiovascular and MedSurg segments, with expectations for above-market growth through 2025-2026 [4] - The WATCHMAN device is a leading product in percutaneous left atrial appendage closure (LAAC), with a projected market expansion of approximately 20% in the coming years [5] - The company is gaining market share in electrophysiology, particularly with the FARAPULSE Pulsed Field Ablation System, which received FDA approval for expanded use in July 2025 [6] - Recent acquisitions, including Intera Oncology and Elutia's BioEnvelope business, support Boston Scientific's growth strategy and expansion into high-growth areas [7] - Emerging markets accounted for 15% of Boston Scientific's consolidated net sales in the first nine months of 2025, indicating significant long-term growth potential [8] Resmed Overview - Resmed is witnessing strong demand for its mask portfolio, including the AirFit and AirTouch ranges, and is focusing on direct-to-consumer markets in regions like China and India [9] - The company has launched new variants of its AirTouch F30i mask and continues to see strong sales from its AirSense device platforms [9] - Resmed is advancing AI integration in its digital health products, including the launch of the personal sleep health digital assistant, Dawn, in the U.S. [11] - The company is optimizing operations to improve gross margins and has made acquisitions like Somnoware and Ectosense to support its 2030 growth strategy [12] Financial Estimates and Performance - The Zacks Consensus Estimate for Boston Scientific's 2025 EPS indicates a year-over-year increase of 21.1% to $3.04, with a slight upward revision in the last 60 days [13] - Resmed's fiscal 2026 EPS consensus estimate of $10.84 reflects a 13.5% improvement over 2025, with a 3.3% increase in estimates over the past 60 days [15] - In the last 12 months, BSX shares have increased by 6.8%, while RMD shares have risen by 5.8% [16] Investment Considerations - Boston Scientific is highlighted for its divisional strength, ongoing momentum with the WATCHMAN device, and strategic acquisitions in high-growth markets [18] - Resmed remains focused on innovation and strong demand for its products, but Boston Scientific is currently viewed as the more attractive investment option based on recent performance [18] - Boston Scientific holds a Zacks Rank 2 (Buy), while Resmed has a Zacks Rank 3 (Hold) [20]

Key Takeaways Resmed's Smart Comfort gets FDA clearance, offering AI-personalized CPAP settings for OSA patients.Resmed leverages AI and real-world sleep data to improve comfort and adherence in CPAP therapy.Resmed's Smart Comfort supports clinicians by easing setup, follow-up, and therapy management.Resmed (RMD) has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S. beta ver ...

Financial Data and Key Metrics Changes - ResMed achieved a 10% year-over-year reported revenue growth in Q4 FY2025, with a gross margin expansion of 230 basis points year-over-year [7][43] - Free cash flow for FY2025 was $1.7 billion, providing significant flexibility for investments and shareholder returns [9] - Net income increased by 22%, and non-GAAP diluted earnings per share rose by 23% [47] Business Line Data and Key Metrics Changes - Device sales globally increased by 8%, while masks and other sales rose by 11% [41] - Residential Care software revenue increased by 9% on a constant currency basis, driven by strong performance in Medifox DAN and HME verticals [42] - In the U.S., Canada, and Latin America, device sales increased by 7%, and masks and other sales increased by 12% [41] Market Data and Key Metrics Changes - Sales in Europe, Asia, and other regions increased by 9% on a constant currency basis [40] - The U.S. healthcare system's demand for home medical equipment remains strong, with ResMed focusing on partnerships with HME providers [11] Company Strategy and Development Direction - ResMed is committed to its ResMed 2030 strategy, aiming to improve the lives of over 500 million people by 2030 [8] - The company is pursuing tuck-in acquisitions to accelerate growth, with recent acquisitions including Sonderware and Vertuox [10] - ResMed is focused on expanding its digital health ecosystem and enhancing its product offerings through innovation in R&D and AI technologies [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating global macro uncertainties, emphasizing a strong balance sheet and operational excellence [9][36] - The company is well-positioned to address the growing demand for sleep apnea and respiratory care solutions, with a focus on expanding home sleep apnea testing capabilities [13][70] - Management highlighted the importance of ongoing investments in marketing and education to drive awareness and demand for sleep health solutions [24][27] Other Important Information - The Board of Directors approved a 13% increase in the quarterly dividend, reflecting confidence in the company's performance [49] - ResMed plans to increase its share buyback program to approximately $150 million per quarter starting in FY2026 [49] Q&A Session Summary Question: Growth in Rest of World Devices - Management noted strong growth in Europe, Asia, and Rest of World Devices at 10%, attributing it to various factors including market dynamics and demand generation activities [53][54] Question: Gross Margin Guidance - Management discussed the elements contributing to gross margin improvement, including foreign currency benefits and operational efficiencies [59][60] Question: Roadmap for Virtuox Post-Acquisition - Management expressed excitement about Virtuox, emphasizing its role in expanding home sleep apnea testing capabilities and integrating with existing products [66][70] Question: U.S. Mask Growth - Management acknowledged low double-digit growth in U.S. masks, attributing it to both market share gains and increased resupply frequency [77][81] Question: Competitive Bidding and Consolidation - Management discussed the potential impact of competitive bidding on the DME space, emphasizing the importance of advocating for patient access to care [86][92]

Financial Data and Key Metrics Changes - ResMed achieved a 10% year-over-year reported revenue growth in Q4 FY2025, with a gross margin expansion of 230 basis points year-over-year [6][40]. - Free cash flow for FY2025 was $1.7 billion, providing significant flexibility for investments and shareholder returns [8][48]. - Net income increased by 22%, and non-GAAP diluted earnings per share rose by 23% [47]. Business Line Data and Key Metrics Changes - Device sales globally increased by 8%, while masks and other sales grew by 11% on a constant currency basis [41]. - Residential Care software revenue increased by 9% on a constant currency basis, driven by strong performance in Medifox DAN and HME verticals [42]. Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 9%, while sales in Europe, Asia, and other regions also rose by 9% on a constant currency basis [40][41]. - Device sales in the U.S., Canada, and Latin America increased by 7%, with masks and other sales up by 12% [41]. Company Strategy and Development Direction - ResMed is focused on building a global digital health ecosystem encompassing sleep health, breathing health, and healthcare delivery in the home [6][7]. - The company aims to achieve its ResMed 2030 goal of improving the lives of over 500 million people [7]. - ResMed is pursuing tuck-in acquisitions to accelerate its growth strategy, with recent acquisitions including Sonderware and Vertuox [9][10]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate global macro uncertainties, including tariffs and trade issues [8][36]. - The company is committed to operational excellence and driving ongoing operating leverage, with expectations for gross margin to be in the range of 61% to 63% in FY2026 [43][44]. Other Important Information - ResMed's Board of Directors authorized a 13% increase in the quarterly dividend for FY2026 and plans to significantly increase share repurchase activity [13][50]. - The company is integrating its residential care software business into the broader organization to enhance operational efficiency [29]. Q&A Session Summary Question: Growth in Rest of World Devices - Management noted strong growth in Europe, Asia, and Rest of World Devices at 10%, attributed to various factors including market dynamics and demand generation activities [54][56]. Question: Gross Margin Guidance - Management highlighted that gross margin improvements were driven by procurement efficiencies and favorable foreign currency movements, with expectations for continued improvements [61][64]. Question: Roadmap for Vertuox Post-Acquisition - Management emphasized that Vertuox is part of a broader strategy to enhance home sleep apnea testing capabilities and improve patient flow through the healthcare system [67][75]. Question: U.S. Mask Growth - Management indicated that U.S. mask growth was driven by product innovations and resupply frequency, with expectations for continued strong performance [80][84]. Question: Competitive Bidding and Consolidation - Management discussed the potential impact of competitive bidding on the DME space, emphasizing the importance of advocating for patient access to care [89][96].

Core Insights - ResMed Inc. reported adjusted earnings per share (EPS) of $2.37 for Q3 fiscal 2025, reflecting an 11.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 0.4% [1] - The company's revenues for the same quarter reached $1.29 billion, marking a 7.5% year-over-year growth and exceeding the Zacks Consensus Estimate by 0.5% [3] Financial Performance - Adjusted gross profit increased by 10.5% to $773.8 million, with an adjusted gross margin of 59.9%, up 138 basis points year over year [9] - Selling, general and administrative expenses rose 6.7% to $245.3 million, while research and development expenses increased by 8.9% to $83.9 million [10] - Adjusted operating income was $444.6 million, up 13% from the previous year, with an adjusted operating margin of 34.4%, expanding by 154 basis points [10] Revenue Breakdown - The Sleep and Breathing Health segment generated revenues of $1.13 billion, an 8% increase year over year, with global device sales totaling $676.2 million, up 6% [6] - In the Residential Care Software segment, revenues grew 9% year over year to $161.2 million, slightly below projections [8] Market Reaction - Following the earnings announcement, ResMed's shares rose by 2.6% in after-market trading [2] Strategic Developments - The company launched the NightOwl, an FDA-cleared home sleep apnea test, and introduced a brand evolution to unify its brand portfolio [15]